Is NCT07081997 recruiting in Reno, NV?

Yes, NCT07081997 is currently recruiting participants at its Reno, NV location. This hypoparathyroidism clinical trial is actively enrolling qualified participants.

How do I join the hypoparathyroidism clinical trial in Reno?

To join this clinical trial in Reno, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Reno clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Hypoparathyroidism Clinical Trial in Reno, NV

About This Hypoparathyroidism Study in Reno

This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg/day. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg/day in adults with hypoparathyroidism. The trial will be conducted in the US.

Sponsor: Ascendis Pharma Bone Diseases A/S

Who Can Participate

Inclusion Criteria

Males and females, ≥18 years of age at the time of providing informed consent

Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks

Receiving doses of palopegteriparatide at or above 30 µg/day For individuals receiving 30 µg/day: evidence that dose is insufficient to keep serum calcium in the normal range, defined as: Documented hypocalcemia within 12 weeks prior to Screening; and/or Standing dose of calcitriol ≥0.25 μg/day, and / or (elemental) calcium ≥1500 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening For individuals receiving 33 µg/day or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium

Confirmation of laboratory parameters (Central and Local) within 2 weeks of screening visit and prior to randomization: 25(OH) vitamin D levels of 20 - 80 ng/mL (49 - 200 nmol/L) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg/dL (≥0.53 mmol/L) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range

Albumin-adjusted sCa 7.8 - 10.6 mg/dL (or 1.95 - 2.64 mmol/L)

Ionized sCa 4.40 - 5.29 mg/dL (1.10 - 1.32 mmol/L) 5\. BMI 17- 40 kg/m2 at Screening 6\. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand 7\. eGFR ≥30 mL/min/1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula

Exclusion Criteria

Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia

Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP

Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin \>30 µg/day, or systemic corticosteroids (other than as replacement therapy)

Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1

Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening

Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening

Use of osteoporosis therapies other than bisphosponate known to influence calcium and bone metabolism within 2 years prior to Screening. Note: use of bisphosphonate (oral or intravenous \[IV\] is not exclusionary

Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.

Increased risk for osteosarcoma

Women who are pregnant, intend to become pregnant, or are lactating

Male who has a female partner who intends to become pregnant or is of childbearing potential and is unwilling to use adequate contraceptive methods during the trial

Diagnosed drug or alcohol dependence within 3 years prior to Screening

Chronic or severe cardiac disease within 26 weeks prior to Screening

Cerebrovascular accident within 5 years prior to Screening.

Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout

Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.

Known allergy or sensitivity to PTH or any of the excipients \[metacresol, mannitol, succinic acid, NaOH/(HCl)\] of the investigational product

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Reno?

Yes, this clinical trial (NCT07081997) has an active research site in Reno, NV that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Hypoparathyroidism Treatment Options in Reno, NV

If you're searching for hypoparathyroidism treatment options in Reno, NV, this clinical trial (NCT07081997) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Reno research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hypoparathyroidism specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all hypoparathyroidism clinical trials near you to find additional studies recruiting in your area.

Hypoparathyroidism Clinical Trial in Reno, NV

Expert Care in Reno

IRB Approved

No-Cost Care

Apply for This Reno Location

Why Participate?

Simple Process